Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.
Related Keywords
Jakub Svoboda , Hospital Of The University Pennsylvania , Data Safety Monitoring Committee , Abramson Cancer Center , Lymphoma Tumor Board , Case Conference ,
comparemela.com © 2020. All Rights Reserved.